Literature DB >> 33417091

Visual field progression in patients with severe glaucoma.

Eugenio J Maul1, Alan Kastner2, Jimena Schmidt2, Jaime A Tapia2, Cristobal Morales2, Eugenio A Maul3.   

Abstract

PURPOSE: To assess the cumulative risk of progression in glaucomatous eyes in the severe stage of disease.
METHODS: This was a retrospective observational study. Patients that had severe damage in at least one eye, as defined by three criteria including a mean deviation of ≤ - 20 dB, were included. Glaucoma progression was defined as a loss of ≥ 2 dB in mean deviation confirmed in three consecutive visual field tests, or a persistent loss of two or more lines of vision-not attributable to non-glaucomatous causes-in three consecutive follow-up examinations. Kaplan-Meier survival analysis was used to assess the cumulative incidence of progression of the first eye to reach endpoint in cases where both eyes were eligible.
RESULTS: A total of 143 eyes from 119 patients, were studied over a mean period of 4.9 ± 2.9 years. Baseline mean deviation was - 25.3 ± 3.6 dB. Twenty-three eyes of 22 patients reached the progression endpoint: 14 eyes by visual field criteria and 9 by visual acuity criteria. The cumulative 5-year risk of progression estimated by Kaplan-Meier analysis was 14.6% (95% confidence interval: 6.1-22.2%).
CONCLUSIONS: In severe glaucoma patients, we found a cumulative incidence of progression of 2.9% per year during the first 5 years of follow-up. Similar incidences have been reported in other studies of glaucoma at different stages of severity.

Entities:  

Keywords:  Glaucoma; Humphrey; Progression; Severe; Visual field damage

Year:  2021        PMID: 33417091     DOI: 10.1007/s00417-020-05036-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  17 in total

1.  Glaucoma with severe field loss at presentation? To operate or not to operate … that is the question.

Authors:  Stephen A Vernon
Journal:  Clin Exp Ophthalmol       Date:  2011-12       Impact factor: 4.207

2.  Outcome of trabeculectomy with mitomycin C in patients with advanced glaucoma.

Authors:  Richard E Stead; Anthony J King
Journal:  Br J Ophthalmol       Date:  2010-12-16       Impact factor: 4.638

3.  Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease.

Authors:  Richard P Mills; Donald L Budenz; Paul P Lee; Robert J Noecker; John G Walt; Lisa R Siegartel; Stacy J Evans; John J Doyle
Journal:  Am J Ophthalmol       Date:  2006-01       Impact factor: 5.258

4.  Factors associated with lifetime risk of open-angle glaucoma blindness.

Authors:  Dorothea Peters; Boel Bengtsson; Anders Heijl
Journal:  Acta Ophthalmol       Date:  2013-07-10       Impact factor: 3.761

5.  Analysis of progressive change in automated visual fields in glaucoma.

Authors:  S D Smith; J Katz; H A Quigley
Journal:  Invest Ophthalmol Vis Sci       Date:  1996-06       Impact factor: 4.799

6.  Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study.

Authors:  Kouros Nouri-Mahdavi; Douglas Hoffman; Anne L Coleman; Gang Liu; Gang Li; Douglas Gaasterland; Joseph Caprioli
Journal:  Ophthalmology       Date:  2004-09       Impact factor: 12.079

7.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.

Authors:  Anders Heijl; M Cristina Leske; Bo Bengtsson; Leslie Hyman; Boel Bengtsson; Mohamed Hussein
Journal:  Arch Ophthalmol       Date:  2002-10

8.  Attitudes of consultant ophthalmologists in the UK to initial management of glaucoma patients presenting with severe visual field loss: a national survey.

Authors:  Richard Stead; Augusto Azuara-Blanco; Anthony J King
Journal:  Clin Exp Ophthalmol       Date:  2011-06-14       Impact factor: 4.207

Review 9.  Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis.

Authors:  Seth R Flaxman; Rupert R A Bourne; Serge Resnikoff; Peter Ackland; Tasanee Braithwaite; Maria V Cicinelli; Aditi Das; Jost B Jonas; Jill Keeffe; John H Kempen; Janet Leasher; Hans Limburg; Kovin Naidoo; Konrad Pesudovs; Alex Silvester; Gretchen A Stevens; Nina Tahhan; Tien Y Wong; Hugh R Taylor
Journal:  Lancet Glob Health       Date:  2017-10-11       Impact factor: 26.763

10.  Treatment of Advanced Glaucoma Study: a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma-study protocol.

Authors:  Anthony J King; Gordon Fernie; Augusto Azuara-Blanco; Jennifer M Burr; Ted Garway-Heath; John M Sparrow; Luke Vale; Jemma Hudson; Graeme MacLennan; Alison McDonald; Keith Barton; John Norrie
Journal:  Br J Ophthalmol       Date:  2017-10-26       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.